Clinical and Translational Oncology

, Volume 8, Issue 11, pp 812–820 | Cite as

HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail»

  • Javier A. MenéndezEmail author
  • Alejandro Vázquez-Martín
  • Santiago Ropero
  • Ramón Colomer
  • Ruth LupuEmail author
  • Josep Trueta
Research Articles



Data derived from epidemiological and experimental studies suggest that alphalinolenic acid (ALA; 18:3n-3), the main ϖ-3 polyunsaturated fatty acid (PUFA) present in the Western diet, may have protective effects in breast cancer risk and metastatic progression. A recent pilot clinical trial assessing the effects of ALA-rich dietary flaxseed on tumor biological markers in postmenopausal patients with primary breast cancer demonstrated significant reductions in tumor growth and in HER2 (erbB-2) oncogene expression.


The molecular mechanism by which ALA inhibits breast cancer cell growth and metastasis formation may involve a direct regulation of HER2, a well-characterized oncogene playing a key role in the etiology, progression and response to some chemo- and endocrine therapies in approximately 20% of breast carcinomas.


Using HER2-specific ELISA, flow cytometry, immunofluorescence microscopy, Western blotting, RT-PCR and HER2 promoter-reporter analyses, we characterized the effects of exogenous supplementation with ALA on the expression of HER2 oncogene, a master key player in the onset and metastasis formation of breast cancer disease. Metabolic status (MTT) assays were performed to evaluate the nature of the cytotoxic interaction between ALA and the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®). To study these issues we used BT-474 and SKBr-3 breast cancer cells, which naturally exhibit amplification of the HER2 oncogene.


ALA treatment dramatically suppressed the expression of HER2-coded p185Her-2/neu oncoprotein as determined by ELISA, flow cytometry, immunofluorescence microscopy and immunoblotting techniques. Interestingly, ALA-induced down-regulation of p185Her-2/neu correlated with a transciptional response as no HER2 mRNA signal could be detected by RT-PCR upon treatment with optimal concentrations of ALA (up to 20 μM). Consistent with these findings, ALA exposure was found to dramatically repress the activity of a Luciferase reporter gene driven by the HER2 promoter. Moreover, the nature of the cytotoxic interaction between ALA and trastuzumab (Herceptin®) revealed a significant synergism as assessed by MTT-based cell viability assays.


i) These findigns reveal that the ω-3 PUFA ALA suppresses overexpression of HER2 oncogene at the transcriptional level, which, in turn, interacts synergistically with anti-HER2 trastuzumab-based immunotherapy.ii) Our results molecularly support a recent randomized double-blind placebo-controlled clinical trial suggesting that ALA may be a potential dietary alternative or adjunct to currently used drugs in the management of HER2-positive breast carcinomas.iii) Considering our previous findings demonstrating the «HER2 upregulatory actions» of the ω-6 PUFA linolenic acid (LA; 18:2n-6) and the «HER2 down-regulatory actions» of the ω-3 PUFA docosahexaenoic acid (DHA; 22:6n-3) and of the ω-9 monounsaturated fatty acid oleic acid (OA; 18:1n-9), it is reasonable to suggest that a low ω-6/ω-3 PUFA ratio and elevated MUFA levels, the two prominent «fat features» of the «Mediterranean diet», should be extremely efficient at blocking HER2 expression in breast cancer cells.


Breast Cancer Breast Cancer Cell Trastuzumab Mediterranean Diet PUFA Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bougnoux P, Koscielny S, Chajes V, Descamps P, Couet C, Calais G. Alphalinolenic acid content of adipose tissue: a host determinant of the risk of early metastasis in breast cancer. Br J Cancer. 1994;70:330–4.PubMedGoogle Scholar
  2. 2.
    Klein V, Chajes V, Germain E, et al. Low alpha-linolenic acid content of adipose tissue is associated with an increased risk of breast cancer. Eur J Cancer. 2000;56: 555–40.Google Scholar
  3. 3.
    Kamano K, Okuyama H, Konishi R, Nagasawa H. Effects of a high-linoleate and high-alpha-linolenate on spontaneous mammary tumorigenesis in mice. Anti-cancer Res. 1989;9:1903–8.Google Scholar
  4. 4.
    Fritsche KL, Johnston PV. Effect of dietary alpha-linolenic acid on growth, metastasis, fatty acid profile and prostaglandin production of two murine mammary adenocarcinomas. J Nutr. 1999;120:1601–9.Google Scholar
  5. 5.
    Hirose M, Masuda A, Ito N, Kamano K, Okuyama H. Effects of dietary perilla oil, soybean oil and safflower oil on 7,12-dimethylbenz(a) anthracene (DMBA) and 1,2-domethylhydrazine (DMH)-induced mammary gland and colon carcinogenesis in female SD rats. Carcinogenesis. 1990; 11:731–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Munoz SF, Silva RA, Lamarque A, Guzmán CA, Eynard AR. Protective capability of dietary Zizyphus mistol seed oil, rich in 18/3 n−3, on the development of two murine mammary gland adenocarcinomas with high and low metastatic potential. Prostaglandins Leukot Essent Fatty Acids. 1995;53:135–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n−3 fatty acids on the growth of human breast cancer cellsin vitro: relationship to peroxides and vitamin E. Breast Cancer Res Treat. 1995; 34:199–212.PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson LU, Chen JM, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005;11: 3828–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature. 1986;319:230–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–28.PubMedCrossRefGoogle Scholar
  14. 14.
    Di Fiore PP, Pierce JH, Kraus MH, et al.erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237:178–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Hudziak RN, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA. 1987;84: 7159–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, et al. Her2/neu gene amplification in ductal carcinomain situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002;11:587–90.PubMedGoogle Scholar
  18. 18.
    Tan M, Yao J, Yu D. Overepression of the c-erbB-2 gene enhanced intrinsic metastasis potencial in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–205.PubMedGoogle Scholar
  19. 19.
    Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia, 2001;6:393–406.PubMedCrossRefGoogle Scholar
  20. 20.
    Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4152–41.Google Scholar
  21. 21.
    Kraus MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related proto-oncogeneerbB-2 in human mammary tumour cell lines by different molecular mechanisms. EMBO J. 1987;6:605–10.PubMedGoogle Scholar
  22. 22.
    Bates NP, Hurst HC. Transcriptional regulation of type 1 receptor tyrosine kinases in the mammary gland. J Mammary Gland Biol Neoplasia. 1997;2:153–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Hurst HC. Update on HER-2 as a target for cancer therapy. TheerbB-2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 2001;3:395–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44.PubMedGoogle Scholar
  26. 26.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.PubMedGoogle Scholar
  27. 27.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.PubMedCrossRefGoogle Scholar
  28. 28.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;544:785–92.Google Scholar
  29. 29.
    Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379–98.PubMedCrossRefGoogle Scholar
  30. 30.
    Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3:269–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Wahle KW, Rotondo D, Heys SD. Polyunsaturated fatty acids and gene expression in mammalian systems. Proc Nutr So. 2003;62:349–60.CrossRefGoogle Scholar
  32. 32.
    Jump DB. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci. 2004; 41:41–78.PubMedCrossRefGoogle Scholar
  33. 33.
    Pégorier JP, Le May C, Girard J. Control of gene expression by fatty acids. J Nutr. 2004;154:2444S-9S.Google Scholar
  34. 34.
    Menendez JA, Ropero S, Lupu R, Colomer R. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Ann Oncol. 2004;15:1719–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Menéndez JA, Lupu R, Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22∶6n−3) synergistically enhances taxanes cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev. 2005;14:263–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Menéndez JA, Vellón L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005;16:359–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Menéndez JA, Vellón L, Colomer R, Lupu R. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. J Natl Cancer Inst. 2005;97:1611–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Menéndez JA, Papadimitropoulou A, Vellón L, Colomer R, Lupu R. A genomic explanation connecting “Mediterranean diet”, olive oil and cancer: Oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA 3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur J Cancer. 2006 Jan 4 [Epub ahead of print].Google Scholar
  39. 39.
    Menéndez JA, Lupu R. RESPONSE: Re: Effect of-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. J Natl Cancer Inst. 2006;98:718–20.Google Scholar
  40. 40.
    Bougnoux P, Giraudeau B, Couet C. Diet, cancer and the lipidome. Cancer Epidemiol Biomarkers Prev. 2006;15:416–21.PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  • Javier A. Menéndez
    • 1
    • 7
    • 2
    Email author
  • Alejandro Vázquez-Martín
    • 1
    • 7
    • 2
  • Santiago Ropero
    • 3
  • Ramón Colomer
    • 1
    • 7
    • 2
  • Ruth Lupu
    • 4
    • 5
    • 6
    Email author
  • Josep Trueta
    • 7
  1. 1.Fundació d'Investigació Biomèdica de Girona Dr. Josep Trueta (IdlBGi)Girona, CataloniaSpain
  2. 2.Hospital Universitari de Girona Dr. Josep TruetaGirona, CataloniaSpain
  3. 3.Eplgenetics LaboratorySpanish National Cancer Centre (CNIO)MadridSpain
  4. 4.Department of MedicineEvanston Northwestern Healthcare Research InstituteEvanstonUSA
  5. 5.Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  6. 6.Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicagoUSA
  7. 7.Institut Catalá d'Oncologia de Girona (ICO Girona)Hospital Universitari de Girona Dr. Josep TruetaGirona, CataloniaSpain

Personalised recommendations